Latest Breaking News On - National major new drug discovery - Page 1 : comparemela.com

Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

/PRNewswire/ 23 Nov, 2023, on the second anniversary of the initial approval for olverembatinib, Ascentage Pharma hosted a ceremony in Suzhou, China,.

United statesHong kongDajun yangYifan zhaiAscentage pharmaInnovent biologicsChina national medical products administrationManufacturing programMajor nationalDrug administrationChinese centerMd anderson cancer centerEuropean unionNational major new drug discoveryNational reimbursement drug listDana farber cancer institute

Ascentage Pharma Announces 2023 Interim Results Highlighting Significant Increase in Sales and Clearance for Global Registrational Phase III Trial

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),.

United statesHong kongAscentage pharmaDajun yangPrnewswire ascentage pharmaAmerican association of cancer researchManufacturing programChina national reimbursement drug listMajor nationalNational major new drug discoveryChina national medical products administrationDana farber cancer instituteDrug administrationMd anderson cancer centerEuropean hematology associationGlobal manufacturing center

Registrational Pivotal Phase III Study of Olverembatinib for the First-Line Treatment of Patients with Ph+ ALL Approved by the CDE in China

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

United statesHong kongInnovent biologicsAscentage pharmaYifan zhaiPrnewswire ascentage pharmaElias jabbourEuropean unionChinese society of clinical oncologyManufacturing programMd anderson cancer centerChina national medical products administrationDrug administrationDana farber cancer instituteNational reimbursement drug listAmerican society of hematology

Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93 8% Signals a Potential Clinical Breakthrough

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

Hong kongUnited statesWestern australiaInnovent biologicsRuihua xuYifan zhaiAscentage pharmaAmerican society of clinical oncologyMd anderson cancer centerMajor nationalEuropean unionDana farber cancer instituteSun yat sen university cancer centerEuropean medicines agencyAmerican society of hematologyChina national medical products administration

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongRhui zhouEli lillyInnovent biologicsAscentage pharmaAdimab incyteDrug administrationEuropean unionIncyte corporationChina national medical products administrationMd anderson cancer centerAmerican society of hematologyManufacturing programNational reimbursement drug listEuropean medicines agency